Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American BrainTumor Consortium Study

PURPOSE: To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its me...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Loghin, Monica E., Prados, Michael D., Wen, Patrick, Junck, Larry, Lieberman, Frank, Fine, Howard, Fink, Karen L., Metha, Minesh, Kuhn, John, Lamborn, Kathleen, Chang, Susan M., Cloughesy, Timothy, DeAngelis, Lisa M., Robins, Ian H., Aldape, Kenneth D., AlfredYung, W.K.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2007
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802002/
https://ncbi.nlm.nih.gov/pubmed/18056194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-07-0874
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares